Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.

Official Title

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Keywords

Uveitis, Non-infectious uveitis, Intermediate-uveitis, Posterior-uveitis, Pan-uveitis, Panuveitis, Izokibep

Eligibility

You can join if…

Open to people ages 18-75

General

  • Subject has provided signed informed consent including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • 18 years to 75 years of age

Type of Subject and Disease Characteristics

  • Subject is diagnosed with non-infectious intermediate-, posterior- or pan-uveitis
  • Active disease defined by the presence of at least 1 of the following criteria in at least 1 eye despite treatment with stable doses of corticosteroids for at least 2 weeks prior to day 1:
    • Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion by dilated indirect ophthalmoscopy, fundus photography, fluorescein angiography (FA), and Spectral-Domain Optical Coherence Tomography (SD-OCT) to determine whether a lesion is active or inactive (the central reading center assessment using FA, fundus photography and/or SD-OCT is required to confirm eligibility prior to day 1).
    • ≥ 2+ vitreous haze (National Eye Institute [NEI]/Standardization of Uveitis Nomenclature [SUN] criteria) by digital indirect ophthalmoscope and fundus photography (the central reading center assessment using fundus photography is required to confirm eligibility prior to day 1).
  • Currently receiving treatment with oral corticosteroids (≥ 7.5 mg/day to ≤ 40 mg/day oral prednisone/prednisolone or corticosteroid equivalent) at a stable dose for at least 2 weeks prior to day 1.

You CAN'T join if...

Disease-related Medical Conditions

  • Subject with isolated anterior uveitis
  • Subject with serpiginous choroidopathy
  • Subject with confirmed or suspected infectious uveitis
  • Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the study
  • Subject with intraocular pressure of ≥ 25 mmHg while on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury
  • Subject with severe vitreous haze that precludes visualization of the fundus prior to first dose of study drug
  • Subject has a contraindication for mydriatic eye drops OR subject cannot be dilated sufficiently well to permit good fundus visualization
  • Subject with best corrected visual acuity (BCVA) < 20 letters (Early Treatment Diabetic Retinopathy Study [ETDRS]) in at least 1 eye prior to first dose of study drug
  • Subject with proliferative or severe non-proliferative retinopathy or clinically significant macular edema due to diabetic retinopathy
  • Subject with neovascular/wet age-related macular degeneration
  • Subject with an abnormality of the vitreo-retinal interface with the potential for macular structural damage independent of the inflammatory process
  • Subject with a history of active scleritis ≤ 12 months of first dose of study drug

Other protocol defined Inclusion/Exclusion criteria may apply

Locations

  • Clinical Research Site accepting new patients
    Los Angeles California 90095-7065 United States
  • Clinical Research Site accepting new patients
    San Francisco California 94109 United States
  • Clinical Research Site accepting new patients
    Beverly Hills California 90211-1841 United States
  • Clinical Research Site accepting new patients
    Los Angeles California 90033-1036 United States
  • Clinical Research Site accepting new patients
    Sacramento California 95825 United States
  • Clinical Research Site accepting new patients
    Pasadena California 91107-3747 United States
  • Clinical Research Site accepting new patients
    Palo Alto California 94303 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
ACELYRIN Inc.
ID
NCT05384249
Phase
Phase 2 Uveitis Research Study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated